BeOne Medicines (BEIGF) Cash & Equivalents (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Cash & Equivalents data on file, last reported at $4.8 billion in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $4.8 billion, up 90.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 90.42% YoY), and the FY2025 annual result was $4.5 billion, up 73.08% from the prior year.
• Cash & Equivalents advanced to $4.8 billion in Q1 2026 per BEIGF's latest filing, from $4.5 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $4.8 billion in Q1 2026 and troughed at $191000.0 in Q3 2022.
• A 5-year average of $3.0 billion and a median of $3.1 billion in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 99.99% in 2022, then soared 1605835.08% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $3.9 billion in 2022, then dropped by 18.03% to $3.2 billion in 2023, then declined by 17.16% to $2.6 billion in 2024, then jumped by 73.08% to $4.5 billion in 2025, then advanced by 5.37% to $4.8 billion in 2026.
• Business Quant data shows BEIGF's Cash & Equivalents at $4.8 billion in Q1 2026, $4.5 billion in Q4 2025, and $4.0 billion in Q3 2025.